SQUAMOUS CELL EA3191

Study #EA3191

A Phase II Randomized Trial of Adjuvant Therapy with Pembrolizumab after Resection of Recurrent / Second Primary Head and Neck Squamous Cell Carcinoma with High Risk Features (ERADICATE)

Back To Clinical Trials